“…ESBL-E occur worldwide in both community and hospital settings (Paterson and Bonomo, 2005;Pitout et al, 2005;Sonda et al, 2016;Storberg, 2014;Luvsansharav et al, 2011), and the reported incidence of infections in paediatric and neonatal populations is increasing (Paterson and Bonomo, 2005;Sonda et al, 2016;Storberg, 2014;Flokas et al, 2017;Peirano and Pitout, 2010;Tansarli et al, 2014;Dramowski et al, 2015;Logan et al, 2014). Clinical infections with ESBL-E are associated with increased morbidity (including prolonged hospital stay), increased healthcare costs, and higher mortality rates compared to infections with non- ESBL-E (Blomberg et al, 2005;Zaoutis et al, 2005;Kim et al, 2002;Ndir et al, 2016). Among neonates, children, and pregnant/ post-partum women, ESBL-E are frequently implicated in urinary tract infections (UTI) (Pitout et al, 2005;Peirano and Pitout, 2010) and bloodstream infections (BSI) (Luvsansharav et al, 2011;Flokas et al, 2017;Dramowski et al, 2015;Zaoutis et al, 2005;Loh and Sivalingam., 2007).…”